Log In
BCIQ
Print this Print this
 

VXM01

  Manage Alerts
Collapse Summary General Information
Company Vaximm AG
DescriptionOral T cell immunotherapy based on the recombinant, live, attenuated Salmonella typhi vaccine strain Ty21a that carries the VEGF receptor 2 (VEGFR-2; KDR/Flk-1) gene
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today